Abstract
Materials/Methods: One hundred five patients with LABC (white 46%, non-white 54%), from three different academic institutions, University of Southern California (33), New York University (36), and Vanderbilt (36), were treated neo-adjuvantly with a regimen that combined paclitaxel and concurrent radiotherapy. Paclitaxel dose (30 mg/m) was given intravenously twice a week for 10-12 weeks, with daily radiotherapy to the breast, axillary and supraclavicular lymph nodes during weeks 2-7. Radiation dose was 1.8 Gy per fraction to a total dose of 45 Gy with an additional tumor boost of 14 Gy at 2 Gy /fraction. After completion of chemoradiation, pathological response in the breast and axillary lymph nodes was assessed at definitive cancer surgery. Post-operative treatment was left to the discretion of the treating physician.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
